Thanks to Jim, immune checkpoint therapy has transformed not only our institution but the entire cancer field, providing a revolutionary new treatment strategy and real hope for countless cancer patients. In addition, Jim’s story stands as one of the best examples of the importance of sustained investment in basic biomedical research. Guest Editorial: Cancer-Letter-10.5.18
Thank you, Jim Allison Read More »
Last year, the FDA issued a landmark approval for the immune therapy drug pembrolizumab (Keytruda) for the treatment of adult and pediatric metastatic tumors whose cells have defects in their DNA repair machinery. This was the first-ever approval of a site-agnostic drug, which targets a tumor based on its genetic profile instead of its anatomic
How precision medicine can help cancer patients Read More »
Nobel Prize in Medicine winner James Allison received a phone call from former VP Joe Biden congratulating him on winning the award. Source: Read More
James Allison receives phone call from former VP Joe Biden Read More »
The Houston scientist whose pioneering research has revolutionized cancer treatment was awarded the 2018 Nobel Prize in Medicine Monday. Dr. Jim Allison, MD Anderson Cancer Center’s chairman of immunology, and Japan’s Tasuku Honjo received the prize for research that’s led to a class of drugs that have cured patients whose disease was considered hopeless. The
Houston scientist Jim Allison wins Nobel Read More »
Jim Allison, today’s winner of the first Nobel prize for cancer therapy along with Kyoto University’s Tasuku Honjo, says he expects immunotherapy to be the “fourth pillar” in cancer treatments, along with radiation, chemotherapy and other gene-targeting treatments. Why it matters: Immunotherapy treatments for cancer had a slow start, but persistent research has led to
Immunotherapy could be the “fourth pillar” of cancer treatments Read More »
Jim Allison has been a good friend and colleague for decades. I am so happy he won the Nobel Prize for his groundbreaking work in immune therapy. Honored to be with him in New York City this morning for the announcement. His science and passion has saved and will continue to save many lives. He
Jim Allison Wins Nobel Prize Read More »
As candidate early detection tests for PDAC come online, one of the key challenges is figuring out who to screen, i.e., at greatest risk. For those with new-onset diabetes which modestly increases overall risk relative to the general population, this model could enrich for those new-onset diabetics harboring an occult PDAC, i.e., optimal candidates for
Model to Determine Risk of Pancreatic Cancer Read More »
Ron DePinho has blazed a wide trail in cancer research. As founding director of the Belfer Institute for Applied Cancer Science at Dana-Farber and former president of MD Anderson Cancer Center in Houston — where he departed after a rocky tenure which he now fiercely defends — DePinho spearheaded translational programs and managed, among other things, to
Houston-based biopharmaceutical company Tvardi Therapeutics Inc., which was co-founded by former University of Texas M.D. Anderson Cancer Center president Dr. Ronald DePinho, secured $9 million in a Series A financing round. Tvardi develops a cancer drug that acts as an inhibitor to STAT3 — a signaling molecule that, when left unrestrained, can sometimes lead to
Former M.D. Anderson president’s new Houston company secures funding, seeks CEO Read More »
With $9 million in series A financing, Tvardi Therapeutics has enough runway to finish a phase 1 trial of its lead asset, an oral STAT3 inhibitor, in solid tumors and to start multiple proof-of-concept studies in additional cancer indications. The Houston-based startup hopes to finish the phase 1 trial by mid-2019 and to start its
Biotech Tvardi Therapeutics raises $9M series A for STAT3 inhibitors Read More »
Sign up for the latest news and updates from Ron DePinho, MD
